Since Th22, Th17, and Th1 cells are major sources of IL-22, IL-17, and IFN-γ, respectively, we further examined alterations in the levels of these cytokines in the treatment response of RA patients to MTX+LEF therapy. The gene discussed is IFNG; the disease is rheumatoid arthritis.